论文部分内容阅读
自1982年我们开始对晚期或复发卵巢癌病人试用他莫西芬(Tamoxifen)进行洽疗。现报道如下。 本组12例(卵巢浆液性乳头状囊腺癌4例,卵巢实质性腺癌3例,卵巢粒层细胞癌1例,卵巢恶性卵泡膜细胞瘤1例,子宫内膜腺癌2例及阴道黑色素瘤1例),其中晚期或复发卵巢癌9例。多因化疗或放疗失败或因化疗引起肝肾功能损害及骨髓抑制,而不能进行化疗者。年龄:48～67岁,中位年龄为
Since 1982, we have started trial treatment of patients with advanced or recurrent ovarian cancer with Tamoxifen. Report as follows now. The group of 12 cases (ovarian serous papillary cystadenocarcinoma in 4 cases, 3 cases of ovarian parenchymal adenocarcinoma, ovarian stratum cell carcinoma in 1 case, 1 case of ovarian malignant achocytoma, 2 cases of endometrial adenocarcinoma and vaginal melanoma Tumor in 1 case), of which 9 cases of advanced or recurrent ovarian cancer. Due to chemotherapy or radiotherapy failure or chemotherapy induced liver and kidney dysfunction and bone marrow suppression, and can not be chemotherapy. Age: 48 ~ 67 years old, the median age is